Science

Apr 14, 2025, 11:13

Myeloma Paper of the Day, April 14th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Study of conditioning, cell dose, schedule and AL amyloidosis ASCT outcome finds full-dose MEL, no rest day and infused CD34 ≥4.5×106/kg -> superior OS; higher TRM if poor PS, hi NT-proBNP, albumin <2.5, lower CD34, no rest.”

“The Impact of Melphalan Conditioning and CD34+ Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis”

Authors: Eli Muchtar, Vaishali Sanchorawala, Hamza Hassan, Ute Hegenbart, Stefan Schönland, Hila Magen, Eden Shkury, Caitlin Sarubbi, Heather Landau, Morie Gertz et al.

More posts featuring Robert Orlowski.

AL Amyloidosis amyloidosis Caitlin Sarubbi cancer Eden Shkury Eli Muchtar Hamza Hassan Heather Landau Hila Magen Morie Gertz Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Stefan Schönland Ute Hegenbart Vaishali Sanchorawala

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research